Novel molecular assay based on ‘Single Nucleotide Fingerprints’ (SNF) for the diagnosis and monitoring of Trypanosomatids.
EDINBURGH, UK and GRANADA, Spain—July 21, 2017—
Researchers at the Centre for Genomics and Oncological Research (GENYO) located in Granada, Spain, in collaboration with DestiNA have developed a novel assay for the diagnosis and monitoring of Trypanosomatids. The method is based on a single-plex PCR, using specific primers that amplify a conserved homology region of Trypanosomatidae species. Amplified fragments are analyzed by DestiNA technology using two DestiNA probes and the four SMART nucleobases with MALDI-ToF for the unique pattern of ‘Single Nucleotide Fingerprints’ (SNF) for each species. This molecular assay can unequivocally identify the trypanosomiasis specie presents in a sample through their unique SNF pattern. The novel assay has been published in the peer-reviewed scientific journal Talanta.
DestiNA has adapted this MALDI-ToF based molecular assay to a colorimetric-based system using low density arrays within a spin-tube. This product provides an easy-to-use and cost effective tool with high sensitivity and specificity. The novel kit permits a rapid identification and differential diagnosis of Chagas disease and Leishmaniasis and monitoring therapeutic responses. For more information regarding this product, please see this page.